Upcoming events – Dermira awaits eczema results and Conatus gets another bash at Nash
Dermira hopes that lebrikizumab can beat Dupixent, while Conatus tries to overcome an earlier Nash setback.
Upcoming events – Dermira turns to sweat while Bristol looks to challenge Merck
Approval decisions are looming for an excessive underarm sweating project, and Opdivo plus Yervoy in MSI-high colorectal cancer.
Where is the IPO class of 2014-15 now?
A golden age for biotech flotations yielded some spectacular blow-ups, but also saw several groups reward investors with premium-priced takeovers.
Small and mid-cap share price gains make up for majors
Deals were a major driver of mid-cap share movement in the first quarter, but pipeline progress and misfires played their parts too.
